Premium
Pre‐morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis
Author(s) -
Pagai Sabrina,
Hyman Theodore,
Shui Amy,
Allred Peggy,
Harms Matthew,
Liu Jingxia,
Maragakis Nicholas,
Schoenfeld David,
Yu Hong,
Atassi Nazem,
Cudkowicz Merit,
Miller Timothy M.
Publication year - 2015
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.24688
Subject(s) - amyotrophic lateral sclerosis , medicine , body mass index , diabetes mellitus , risk factor , type 2 diabetes , population , clinical endpoint , type 2 diabetes mellitus , proportional hazards model , hazard ratio , multivariate analysis , clinical trial , disease , confidence interval , endocrinology , environmental health
The aim of this study was to determine whether a history of pre‐morbid type 2 diabetes mellitus (DM2) is a prognostic factor in amyotrophic lateral sclerosis (ALS). Methods: The relationship between DM2 and survival was analyzed in a study population consisting of 1,322 participants from 6 clinical trials. Results: Survival did not differ by diabetes status (log‐rank test, P = 0.98), but did differ by body mass index (BMI) (log‐rank test, P = 0.008). In multivariate analysis, there was no significant association between diabetes and survival ( P = 0.18), but the risk of reaching a survival endpoint decreased by 4% for each unit increase in baseline BMI (HR 0.96, 95% CI 0.94–0.99, P = 0.001). DM2 was less prevalent among ALS clinical trial participants than predicted. Conclusions: A history of pre‐morbid DM2 is not an independent prognostic factor in ALS clinical trial databases. The low DM2 prevalence rate should be examined in a large, prospective study to determine whether DM2 affects ALS risk. Muscle Nerve 52:339–343, 2015